NCT03278782 2026-01-09Study of Pembrolizumab (MK-3475) in Combination With RomidepsinM.D. Anderson Cancer CenterPhase 1/2 Active not recruiting39 enrolled
NCT03598998 2025-06-26Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell LymphomasCity of Hope Medical CenterPhase 1/2 Active not recruiting13 enrolled 12 charts
NCT03432741 2025-05-26Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast CancerMayo ClinicPhase 1 Terminated17 enrolled